mRNA Covid-19 vaccines in pregnancy: A systematic review.
| Title: | mRNA Covid-19 vaccines in pregnancy: A systematic review. |
|---|---|
| Authors: | Pratama, Nando Reza, Wafa, Ifan Ali, Budi, David Setyo, Putra, Manesha, Wardhana, Manggala Pasca, Wungu, Citrawati Dyah Kencono |
| Source: | PLoS ONE; 2/2/2022, Vol. 17 Issue 2, p1-21, 21p |
| Subject Terms: | COVID-19 vaccines, COVID-19, ANTIBODY formation, MATERNALLY acquired immunity, PREGNANT women, PREGNANCY |
| Abstract: | Objective: Pregnancy is a known risk factor for severe Coronavirus disease 2019. It is important to develop safe vaccines that elicit strong maternal and fetal antibody responses. Methods: Registries (ClinicalTrials.gov, the WHO Clinical Trial Registry, and the European Union Clinical Trial Registry) and databases (MEDLINE, ScienceDirect, Cochrane Library, Proquest, Springer, medRxiv, and bioRxiv) were systematically searched in June 20–22, 2021, for research articles pertaining to Covid-19 and pregnancy. Manual searches of bioRxiv and medRxiv were also conducted. Inclusion criteria were studies that focused on Covid-19 vaccination among pregnant women, while review articles and non-human studies were excluded. Infection rate, maternal antibody response, transplacental antibody transfer, and adverse events were described. Results: There were 13 observational studies with a total of 48,039 pregnant women who received mRNA vaccines. Of those, three studies investigated infection rate, six studies investigated maternal antibody response, seven studies investigated antibody transfer, three studies reported local adverse events, and five studies reported systemic adverse events. The available data suggested that the mRNA-based vaccines (Pfizer–BioNTech and Moderna) can prevent future SARS-CoV-2 infection. These vaccines did not show clear harm in pregnancy. The most commonly encountered adverse reactions were pain at the injection site, fatigue, and headache, but these were transient. Antibody responses were rapid after the first vaccine dose. After the booster, antibody responses were stronger and associated with better transplacental antibody transfer. Longer intervals between first vaccination dose and delivery were also associated with higher antibody fetal IgG and a better antibody transfer ratio. Conclusions: The SARS-CoV-2 mRNA vaccines are encouraged for pregnancy. These vaccines can be a safe option for pregnant women and their fetuses. Two vaccine doses are recommended for more robust maternal and fetal antibody responses. Longer latency is associated with higher fetal antibody responses. Further research about its long-term effect on pregnancy is needed. Systematic review registration: PROSPERO (CRD42021261684). [ABSTRACT FROM AUTHOR] |
| Copyright of PLoS ONE is the property of Public Library of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Complementary Index |
| Full text is not displayed to guests. | Login for full access. |
| FullText | Links: – Type: pdflink Text: Availability: 1 CustomLinks: – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edb&genre=article&issn=19326203&ISBN=&volume=17&issue=2&date=20220202&spage=1&pages=1-21&title=PLoS ONE&atitle=mRNA%20Covid-19%20vaccines%20in%20pregnancy%3A%20A%20systematic%20review.&aulast=Pratama%2C%20Nando%20Reza&id=DOI:10.1371/journal.pone.0261350 Name: Full Text Finder (for New FTF UI) (s8985755) Category: fullText Text: Find It @ SCU Libraries MouseOverText: Find It @ SCU Libraries |
|---|---|
| Header | DbId: edb DbLabel: Complementary Index An: 155027859 RelevancyScore: 938 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 937.567626953125 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: mRNA Covid-19 vaccines in pregnancy: A systematic review. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Pratama%2C+Nando+Reza%22">Pratama, Nando Reza</searchLink><br /><searchLink fieldCode="AR" term="%22Wafa%2C+Ifan+Ali%22">Wafa, Ifan Ali</searchLink><br /><searchLink fieldCode="AR" term="%22Budi%2C+David+Setyo%22">Budi, David Setyo</searchLink><br /><searchLink fieldCode="AR" term="%22Putra%2C+Manesha%22">Putra, Manesha</searchLink><br /><searchLink fieldCode="AR" term="%22Wardhana%2C+Manggala+Pasca%22">Wardhana, Manggala Pasca</searchLink><br /><searchLink fieldCode="AR" term="%22Wungu%2C+Citrawati+Dyah+Kencono%22">Wungu, Citrawati Dyah Kencono</searchLink> – Name: TitleSource Label: Source Group: Src Data: PLoS ONE; 2/2/2022, Vol. 17 Issue 2, p1-21, 21p – Name: Subject Label: Subject Terms Group: Su Data: <searchLink fieldCode="DE" term="%22COVID-19+vaccines%22">COVID-19 vaccines</searchLink><br /><searchLink fieldCode="DE" term="%22COVID-19%22">COVID-19</searchLink><br /><searchLink fieldCode="DE" term="%22ANTIBODY+formation%22">ANTIBODY formation</searchLink><br /><searchLink fieldCode="DE" term="%22MATERNALLY+acquired+immunity%22">MATERNALLY acquired immunity</searchLink><br /><searchLink fieldCode="DE" term="%22PREGNANT+women%22">PREGNANT women</searchLink><br /><searchLink fieldCode="DE" term="%22PREGNANCY%22">PREGNANCY</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Objective: Pregnancy is a known risk factor for severe Coronavirus disease 2019. It is important to develop safe vaccines that elicit strong maternal and fetal antibody responses. Methods: Registries (ClinicalTrials.gov, the WHO Clinical Trial Registry, and the European Union Clinical Trial Registry) and databases (MEDLINE, ScienceDirect, Cochrane Library, Proquest, Springer, medRxiv, and bioRxiv) were systematically searched in June 20–22, 2021, for research articles pertaining to Covid-19 and pregnancy. Manual searches of bioRxiv and medRxiv were also conducted. Inclusion criteria were studies that focused on Covid-19 vaccination among pregnant women, while review articles and non-human studies were excluded. Infection rate, maternal antibody response, transplacental antibody transfer, and adverse events were described. Results: There were 13 observational studies with a total of 48,039 pregnant women who received mRNA vaccines. Of those, three studies investigated infection rate, six studies investigated maternal antibody response, seven studies investigated antibody transfer, three studies reported local adverse events, and five studies reported systemic adverse events. The available data suggested that the mRNA-based vaccines (Pfizer–BioNTech and Moderna) can prevent future SARS-CoV-2 infection. These vaccines did not show clear harm in pregnancy. The most commonly encountered adverse reactions were pain at the injection site, fatigue, and headache, but these were transient. Antibody responses were rapid after the first vaccine dose. After the booster, antibody responses were stronger and associated with better transplacental antibody transfer. Longer intervals between first vaccination dose and delivery were also associated with higher antibody fetal IgG and a better antibody transfer ratio. Conclusions: The SARS-CoV-2 mRNA vaccines are encouraged for pregnancy. These vaccines can be a safe option for pregnant women and their fetuses. Two vaccine doses are recommended for more robust maternal and fetal antibody responses. Longer latency is associated with higher fetal antibody responses. Further research about its long-term effect on pregnancy is needed. Systematic review registration: PROSPERO (CRD42021261684). [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Group: Ab Data: <i>Copyright of PLoS ONE is the property of Public Library of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=155027859 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1371/journal.pone.0261350 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 21 StartPage: 1 Subjects: – SubjectFull: COVID-19 vaccines Type: general – SubjectFull: COVID-19 Type: general – SubjectFull: ANTIBODY formation Type: general – SubjectFull: MATERNALLY acquired immunity Type: general – SubjectFull: PREGNANT women Type: general – SubjectFull: PREGNANCY Type: general Titles: – TitleFull: mRNA Covid-19 vaccines in pregnancy: A systematic review. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Pratama, Nando Reza – PersonEntity: Name: NameFull: Wafa, Ifan Ali – PersonEntity: Name: NameFull: Budi, David Setyo – PersonEntity: Name: NameFull: Putra, Manesha – PersonEntity: Name: NameFull: Wardhana, Manggala Pasca – PersonEntity: Name: NameFull: Wungu, Citrawati Dyah Kencono IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 02 Text: 2/2/2022 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 19326203 Numbering: – Type: volume Value: 17 – Type: issue Value: 2 Titles: – TitleFull: PLoS ONE Type: main |
| ResultId | 1 |